Want to see ALXO full AI Analyst Report?
ALX Oncology Holdings (ALXO) Ratios
ALX Oncology Holdings Ratios
ALXO's free cash flow for Q2 2026 was $-16.07M. For the 2026 fiscal year, ALXO's free cash flow was decreased by $-17.00K and operating cash flow was $-16.06M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.07 | 7.26 | 5.24 | 9.57 | 24.00 |
| Quick Ratio | 2.07 | 7.26 | 5.24 | 9.57 | 24.00 |
| Cash Ratio | 0.67 | 0.95 | 0.62 | 1.72 | 23.78 |
| Solvency Ratio | -3.05 | -3.92 | -3.03 | -2.86 | -4.87 |
| Operating Cash Flow Ratio | -3.43 | -6.59 | -3.62 | -3.15 | -4.45 |
| Short-Term Operating Cash Flow Coverage | -16.13 | -280.26 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 17.66M | $ 100.19M | $ 135.82M | $ 227.94M | $ 349.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.11 | 0.07 | 0.03 | 0.00 |
| Debt-to-Equity Ratio | 0.20 | 0.15 | 0.09 | 0.04 | 0.00 |
| Debt-to-Capital Ratio | 0.17 | 0.13 | 0.08 | 0.04 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.08 | 0.05 | 0.03 | 0.00 |
| Financial Leverage Ratio | 2.27 | 1.30 | 1.28 | 1.16 | 1.05 |
| Debt Service Coverage Ratio | -14.58 | -61.11 | -101.22 | -516.39 | -6415.31 |
| Interest Coverage Ratio | -64.93 | -82.40 | -108.80 | -535.45 | -6427.31 |
| Debt to Market Cap | 0.09 | 0.11 | 0.02 | 0.02 | 0.00 |
| Interest Debt Per Share | 0.13 | 0.36 | 0.44 | 0.26 | 0.02 |
| Net Debt to EBITDA | 0.11 | 0.00 | 0.03 | 0.31 | 4.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.05% | 99.97% |
| EBT Per EBIT | 97.76% | 94.65% | 94.44% | 96.85% | 99.92% |
| Return on Assets (ROA) | -172.23% | -91.25% | -66.30% | -40.29% | -21.95% |
| Return on Equity (ROE) | -391.42% | -118.69% | -84.76% | -46.87% | -22.99% |
| Return on Capital Employed (ROCE) | -301.57% | -110.20% | -82.44% | -45.81% | -22.90% |
| Return on Invested Capital (ROIC) | -261.95% | -108.24% | -81.81% | -45.64% | -22.85% |
| Return on Tangible Assets | -172.23% | -91.25% | -66.30% | -40.29% | -21.95% |
| Earnings Yield | -167.72% | -154.77% | -25.12% | -26.92% | -9.64% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.57 | -2.34 | -3.03 | -2.19 | -1.69 |
| Free Cash Flow Per Share | -1.57 | -2.35 | -3.06 | -2.23 | -1.81 |
| Dividend Paid and CapEx Coverage Ratio | -396.90 | -272.73 | -102.33 | -62.52 | -13.83 |
| Capital Expenditure Coverage Ratio | -396.90 | -272.73 | -102.33 | -62.52 | -13.83 |
| Operating Cash Flow Coverage Ratio | -16.13 | -7.18 | -7.58 | -8.55 | -91.78 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -139.12% | -140.43% | -20.57% | -19.76% | -8.43% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.59 | -0.65 | -3.98 | -3.71 | -10.38 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.33 | 0.77 | 3.37 | 1.74 | 2.39 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.72 | -0.71 | -4.86 | -5.06 | -11.86 |
| Price-to-Operating Cash Flow Ratio | -0.72 | -0.71 | -4.91 | -5.14 | -12.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.02 | -0.17 | -0.08 | -0.17 |
| Enterprise Value Multiple | -0.50 | -0.65 | -4.01 | -3.42 | -6.03 |
| Enterprise Value | 49.48M | 86.54M | 634.88M | 420.29M | 503.29M |
| EV to EBITDA | -0.50 | -0.65 | -4.01 | -3.42 | -6.03 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.59 | -0.71 | -4.82 | -4.64 | -6.89 |
| EV to Operating Cash Flow | -0.59 | -0.71 | -4.87 | -4.71 | -7.39 |
| Tangible Book Value Per Share | 0.48 | 2.18 | 4.41 | 6.47 | 9.01 |
| Shareholders’ Equity Per Share | 0.48 | 2.18 | 4.41 | 6.47 | 9.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.90 | -2.58 | -3.74 | -3.03 | -2.07 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.01 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.83 | 0.90 | 0.81 | 0.72 | 0.82 |
Currency in USD
